LAG-3 and PD-L1 are often found to be co-expressed on tumor-infiltrating T cells, and dual blockade of LAG-3 and PD-1 has shown synergistic anti-tumor efficacy in preclinical studies [59,60]. Here, PDCD1 is linked to neoplasm.